Skip to main content
Erschienen in: Clinical Rheumatology 1/2016

01.01.2016 | Case Based Review

Spinal non-Hodgkin’s lymphoma mimicking a flare of disease in a patient with ankylosing spondylitis treated with anti-TNF agents: case report and review of the literature

verfasst von: Sara Monti, Nicola Boffini, Marco Lucioni, Marco Paulli, Carlomaurizio Montecucco, Roberto Caporali

Erschienen in: Clinical Rheumatology | Ausgabe 1/2016

Einloggen, um Zugang zu erhalten

Abstract

We report the case of a 52-year-old man with long-standing HLAB27-positive ankylosing spondylitis treated with anti-tumour necrosis factor (TNF) alpha therapy who was admitted to our rheumatology department complaining of increasing lumbar and buttock pain radiating to the posterior thigh, associated with numbness in the leg, gait disturbance and low-grade fever. The clinical picture was initially interpreted as a flare of disease but was not responsive to treatment. A contrast-enhanced spinal MRI was performed with evidence of a diffuse signal abnormality involving the sacroiliac joints and the spine, with evidence of spondylodiscitis of L5 and with a lesion causing L5-S1 root compression and infiltrating the iliopsoas muscle. These findings confirmed the possibility of a reactivation of disease associated with an infectious process. The most frequent causes of infectious spondylodiscitis were excluded, and a biopsy was then performed. Histological analysis revealed a high-grade B-cell non-Hodgkin’s lymphoma of the spine. This case highlights how a differential diagnosis of low back pain with neurological symptoms can be particularly troublesome in ankylosing spondylitis and that continuous vigilance is warranted in patients treated with long-term immunosuppressive therapies.
Literatur
2.
Zurück zum Zitat Hochberg MC, Silman AJ, Smolen JS et al (2011) Rheumatology. Mosby Elsevier, Philadelphia Hochberg MC, Silman AJ, Smolen JS et al (2011) Rheumatology. Mosby Elsevier, Philadelphia
3.
Zurück zum Zitat Pallavicini FB, Caporali R, Sarzi-Puttini P et al (2010) Tumour necrosis factor antagonist therapy and cancer development: analysis of the LORHEN registry. Autoimmun Rev 9:175–180PubMedCrossRef Pallavicini FB, Caporali R, Sarzi-Puttini P et al (2010) Tumour necrosis factor antagonist therapy and cancer development: analysis of the LORHEN registry. Autoimmun Rev 9:175–180PubMedCrossRef
4.
Zurück zum Zitat Zintzaras E, Voulgarelis M, Moutsopoulos HM (2005) The risk of lymphoma development in autoimmune diseases: a meta-analysis. Arch Intern Med 165:2337–2344PubMedCrossRef Zintzaras E, Voulgarelis M, Moutsopoulos HM (2005) The risk of lymphoma development in autoimmune diseases: a meta-analysis. Arch Intern Med 165:2337–2344PubMedCrossRef
5.
Zurück zum Zitat Askling J, Klareskog L, Blomqvist P et al (2006) Risk for malignant lymphoma in ankylosing spondylitis: a nationwide Swedish case-control study. Ann Rheum Dis 65:1184–1187PubMedPubMedCentralCrossRef Askling J, Klareskog L, Blomqvist P et al (2006) Risk for malignant lymphoma in ankylosing spondylitis: a nationwide Swedish case-control study. Ann Rheum Dis 65:1184–1187PubMedPubMedCentralCrossRef
6.
Zurück zum Zitat Mariette X, Tubach F, Bagheri H et al (2010) Lymphoma in patients treated with anti-TNF: results of the 3-year prospective French RATIO registry. Ann Rheum Dis 69:400–408PubMedPubMedCentralCrossRef Mariette X, Tubach F, Bagheri H et al (2010) Lymphoma in patients treated with anti-TNF: results of the 3-year prospective French RATIO registry. Ann Rheum Dis 69:400–408PubMedPubMedCentralCrossRef
8.
Zurück zum Zitat Nannini C, Cantini F, Niccoli L et al (2009) Single-centre series and systematic review of randomized controlled trials of malignancies in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis receiving anti-tumor necrosis factor alpha therapy: is there a need for more comprehensive screening procedures? Arthritis Rheum 61:801–812PubMedCrossRef Nannini C, Cantini F, Niccoli L et al (2009) Single-centre series and systematic review of randomized controlled trials of malignancies in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis receiving anti-tumor necrosis factor alpha therapy: is there a need for more comprehensive screening procedures? Arthritis Rheum 61:801–812PubMedCrossRef
9.
Zurück zum Zitat the Ankylosing Spondylitis Study for the Evaluation of Recombinant Infliximab Therapy Study Group, Van der Heijde D, Dijkmans B, Geusens P, Sieper J, De Woody K, Williamson P et al (2005) Efficacy and safety of infliximab in patients with ankylosing spondylitis: results of a randomized, placebo-controlled trial (ASSERT). Arthritis Rheum 52:582–591CrossRef the Ankylosing Spondylitis Study for the Evaluation of Recombinant Infliximab Therapy Study Group, Van der Heijde D, Dijkmans B, Geusens P, Sieper J, De Woody K, Williamson P et al (2005) Efficacy and safety of infliximab in patients with ankylosing spondylitis: results of a randomized, placebo-controlled trial (ASSERT). Arthritis Rheum 52:582–591CrossRef
10.
Zurück zum Zitat Braun J, Brandt J, Listing J et al (2002) Treatment of active ankylosing spondylitis with infliximab: a randomized controlled multicenter trial. Lancet 359:1187–1193PubMedCrossRef Braun J, Brandt J, Listing J et al (2002) Treatment of active ankylosing spondylitis with infliximab: a randomized controlled multicenter trial. Lancet 359:1187–1193PubMedCrossRef
11.
Zurück zum Zitat Braun J, van der Horst-Bruinsma IE, Huang F et al (2011) Clinical efficacy and safety of etanercept versus sulfasalazine in patients with ankylosing spondylitis: a randomized, double-blind trial. Arthritis Rheum 63:1543–1551PubMedCrossRef Braun J, van der Horst-Bruinsma IE, Huang F et al (2011) Clinical efficacy and safety of etanercept versus sulfasalazine in patients with ankylosing spondylitis: a randomized, double-blind trial. Arthritis Rheum 63:1543–1551PubMedCrossRef
12.
Zurück zum Zitat Caporali R, Pallavicini FB, Filippini M et al (2009) Treatment of rheumatoid arthritis with anti-TNF-alpha agents: a reappraisal. Autoimmun Rev 8:274–280PubMedCrossRef Caporali R, Pallavicini FB, Filippini M et al (2009) Treatment of rheumatoid arthritis with anti-TNF-alpha agents: a reappraisal. Autoimmun Rev 8:274–280PubMedCrossRef
13.
Zurück zum Zitat Leombruno JP, Einarson TR, Keystone EC (2009) The safety of anti-tumour necrosis factor treatments in rheumatoid arthritis: meta and exposure-adjusted pooled analyses of serious adverse events. Ann Rheum Dis 68:1136–1145PubMedCrossRef Leombruno JP, Einarson TR, Keystone EC (2009) The safety of anti-tumour necrosis factor treatments in rheumatoid arthritis: meta and exposure-adjusted pooled analyses of serious adverse events. Ann Rheum Dis 68:1136–1145PubMedCrossRef
14.
Zurück zum Zitat Burmester GR, Panaccione R, Gordon KB et al (2013) Adalimumab: long-term safety in 23 458 patients from global clinical trials in rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondylitis, psoriatic arthritis, psoriasis and Crohn’s disease. Ann Rheum Dis 72:517–524PubMedPubMedCentralCrossRef Burmester GR, Panaccione R, Gordon KB et al (2013) Adalimumab: long-term safety in 23 458 patients from global clinical trials in rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondylitis, psoriatic arthritis, psoriasis and Crohn’s disease. Ann Rheum Dis 72:517–524PubMedPubMedCentralCrossRef
15.
Zurück zum Zitat Geborek P, Bladström A, Turesson C et al (2005) Tumour necrosis factor blockers do not increase overall tumour risk in patients with rheumatoid arthritis, but may be associated with an increased risk of lymphomas. Ann Rheum Dis 64:699–703PubMedPubMedCentralCrossRef Geborek P, Bladström A, Turesson C et al (2005) Tumour necrosis factor blockers do not increase overall tumour risk in patients with rheumatoid arthritis, but may be associated with an increased risk of lymphomas. Ann Rheum Dis 64:699–703PubMedPubMedCentralCrossRef
16.
Zurück zum Zitat Wolfe F, Michaud K (2007) The effect of methotrexate and anti-tumor necrosis factor therapy on the risk of lymphoma in rheumatoid arthritis in 19,562 patients during 89,710 person-years of observation. Arthritis Rheum 56:1433–1439PubMedCrossRef Wolfe F, Michaud K (2007) The effect of methotrexate and anti-tumor necrosis factor therapy on the risk of lymphoma in rheumatoid arthritis in 19,562 patients during 89,710 person-years of observation. Arthritis Rheum 56:1433–1439PubMedCrossRef
17.
Zurück zum Zitat Mariette X, Matucci-Cerinic M, Pavelka K et al (2011) Malignancies associated with tumor necrosis factor inhibitors in registries and prospective observational studies: a systematic review and meta-analysis. Ann Rheum Dis 70:1895–1904PubMedCrossRef Mariette X, Matucci-Cerinic M, Pavelka K et al (2011) Malignancies associated with tumor necrosis factor inhibitors in registries and prospective observational studies: a systematic review and meta-analysis. Ann Rheum Dis 70:1895–1904PubMedCrossRef
18.
Zurück zum Zitat Wolfe F, Michaud K (2004) Lymphoma in rheumatoid arthritis: the effect of methotrexate and anti-tumor necrosis factor therapy in 18,572 patients. Arthritis Rheum 50:1740–1751PubMedCrossRef Wolfe F, Michaud K (2004) Lymphoma in rheumatoid arthritis: the effect of methotrexate and anti-tumor necrosis factor therapy in 18,572 patients. Arthritis Rheum 50:1740–1751PubMedCrossRef
19.
Zurück zum Zitat Greenberg J, Strand V, Keystone E, at al (2007) TNF inhibitors (TNF-I) and risk of malignancy in 8,072 RA patients followed over 15,495 patient years (Abstract 282) American College of Rheumatology Annual Meeting Greenberg J, Strand V, Keystone E, at al (2007) TNF inhibitors (TNF-I) and risk of malignancy in 8,072 RA patients followed over 15,495 patient years (Abstract 282) American College of Rheumatology Annual Meeting
20.
Zurück zum Zitat Askling J, Baecklund E, Granath F et al (2009) Anti-tumor necrosis factor therapy in rheumatoid arthritis and risk of malignant lymphomas: relative risks and time trends in the Swedish Biologics Register. Ann Rheum Dis 68:648–653PubMedCrossRef Askling J, Baecklund E, Granath F et al (2009) Anti-tumor necrosis factor therapy in rheumatoid arthritis and risk of malignant lymphomas: relative risks and time trends in the Swedish Biologics Register. Ann Rheum Dis 68:648–653PubMedCrossRef
21.
Zurück zum Zitat Sarzi-Puttini P, Antivalle M, Marchesoni A et al (2008) Efficacy and safety of anti-TNF agents in the Lombardy rheumatoid arthritis network (LORHEN). Reumatismo 60:290–295PubMed Sarzi-Puttini P, Antivalle M, Marchesoni A et al (2008) Efficacy and safety of anti-TNF agents in the Lombardy rheumatoid arthritis network (LORHEN). Reumatismo 60:290–295PubMed
22.
Zurück zum Zitat Baraliakos X, Listing J, Fritz C, Haibel H, Alten R, Burmester GR, Krause A, Schewe S, Schneider M, Sörensen H, Schmidt R, Sieper J, Braun J (2011) Persistent clinical efficacy and safety of infliximab in ankylosing spondylitis after 8 years—early clinical response predicts long-term outcome. Rheumatology (Oxford) 50:1690–1699CrossRef Baraliakos X, Listing J, Fritz C, Haibel H, Alten R, Burmester GR, Krause A, Schewe S, Schneider M, Sörensen H, Schmidt R, Sieper J, Braun J (2011) Persistent clinical efficacy and safety of infliximab in ankylosing spondylitis after 8 years—early clinical response predicts long-term outcome. Rheumatology (Oxford) 50:1690–1699CrossRef
23.
Zurück zum Zitat Baraliakos X, Haibel H, Fritz C, Listing J, Heldmann F, Braun J, Sieper J (2013) Long-term outcome of patients with active ankylosing spondylitis with etanercept-sustained efficacy and safety after seven years. Arthritis Res Ther 15:R67PubMedPubMedCentralCrossRef Baraliakos X, Haibel H, Fritz C, Listing J, Heldmann F, Braun J, Sieper J (2013) Long-term outcome of patients with active ankylosing spondylitis with etanercept-sustained efficacy and safety after seven years. Arthritis Res Ther 15:R67PubMedPubMedCentralCrossRef
24.
Zurück zum Zitat Carmona L, Gómez-Reino JJ, BIOBADASER Group (2006) Survival of TNF antagonists in spondylarthritis is better than in rheumatoid arthritis. Data from the Spanish registry BIOBADASER. Arthritis Res Ther 8:R72PubMedPubMedCentralCrossRef Carmona L, Gómez-Reino JJ, BIOBADASER Group (2006) Survival of TNF antagonists in spondylarthritis is better than in rheumatoid arthritis. Data from the Spanish registry BIOBADASER. Arthritis Res Ther 8:R72PubMedPubMedCentralCrossRef
25.
Zurück zum Zitat Jantunen E, Myllykangas-Luosujärvi R, Kaipiainen-Seppänen O (2000) Autologous stem cell transplantation in a lymphoma patient with a long history of ankylosing spondylitis. Rheumatology (Oxford) 39:563–564CrossRef Jantunen E, Myllykangas-Luosujärvi R, Kaipiainen-Seppänen O (2000) Autologous stem cell transplantation in a lymphoma patient with a long history of ankylosing spondylitis. Rheumatology (Oxford) 39:563–564CrossRef
26.
Zurück zum Zitat Khan SY, Hutchinson DG (2004) Primary synovial non-Hodgkin’s lymphoma in association with ankylosing spondylitis. Rheumatology (Oxford) 43:391CrossRef Khan SY, Hutchinson DG (2004) Primary synovial non-Hodgkin’s lymphoma in association with ankylosing spondylitis. Rheumatology (Oxford) 43:391CrossRef
27.
Zurück zum Zitat Kim YS, Kim HS (2012) Ankylosing spondylitis accompanying with Hodgkin’s lymphoma. Int J Rheum Dis 15:e68–e70PubMedCrossRef Kim YS, Kim HS (2012) Ankylosing spondylitis accompanying with Hodgkin’s lymphoma. Int J Rheum Dis 15:e68–e70PubMedCrossRef
28.
Zurück zum Zitat Aksu K, Cagirgan S, Ozsan N et al (2011) Non-Hodgkin’s lymphoma following treatment with etanercept in ankylosing spondylitis. Rheumatol Int 31:1645–1647PubMedCrossRef Aksu K, Cagirgan S, Ozsan N et al (2011) Non-Hodgkin’s lymphoma following treatment with etanercept in ankylosing spondylitis. Rheumatol Int 31:1645–1647PubMedCrossRef
29.
Zurück zum Zitat Aksu K, Donmez A, Ertan Y et al (2007) Hodgkin’s lymphoma following treatment with etanercept in ankylosing spondylitis. Rheumatol Int 28:185–187PubMedCrossRef Aksu K, Donmez A, Ertan Y et al (2007) Hodgkin’s lymphoma following treatment with etanercept in ankylosing spondylitis. Rheumatol Int 28:185–187PubMedCrossRef
30.
Zurück zum Zitat Jung KH, Lim MJ, Kwon SR et al (2013) Angioimmunoblastic T cell lymphoma in an ankylosing spondylitis patient treated with etanercept. Mod Rheumatol 23:817–822PubMedCrossRef Jung KH, Lim MJ, Kwon SR et al (2013) Angioimmunoblastic T cell lymphoma in an ankylosing spondylitis patient treated with etanercept. Mod Rheumatol 23:817–822PubMedCrossRef
31.
Zurück zum Zitat Mally R, Sharma M, Khan S et al (2011) Primary lumbo-sacral spinal epidural non-Hodgkin’s lymphoma: a case report and review of literature. Asian Spine J 5:192–195PubMedPubMedCentralCrossRef Mally R, Sharma M, Khan S et al (2011) Primary lumbo-sacral spinal epidural non-Hodgkin’s lymphoma: a case report and review of literature. Asian Spine J 5:192–195PubMedPubMedCentralCrossRef
33.
Zurück zum Zitat Toussirot E, Chataigner H, Pépin L et al (2009) Spinal cord compression complicating aseptic spondylodiscitis in ankylosing spondylitis. Clin Exp Rheumatol 27:654–657PubMed Toussirot E, Chataigner H, Pépin L et al (2009) Spinal cord compression complicating aseptic spondylodiscitis in ankylosing spondylitis. Clin Exp Rheumatol 27:654–657PubMed
34.
Zurück zum Zitat BSRBR Control Centre Consortium, British Society for Rheumatology Biologics Register, Galloway JB, Hyrich KL, Mercer LK, Dixon WG, Fu B, Ustianowski AP, Watson KD, Lunt M, Symmons DP (2011) Anti-TNF therapy is associated with an increased risk of serious infections in patients with rheumatoid arthritis especially in the first 6 months of treatment: updated results from the British Society for Rheumatology Biologics Register with special emphasis on risks in the elderly. Rheumatology 50:124–131PubMedCentralCrossRef BSRBR Control Centre Consortium, British Society for Rheumatology Biologics Register, Galloway JB, Hyrich KL, Mercer LK, Dixon WG, Fu B, Ustianowski AP, Watson KD, Lunt M, Symmons DP (2011) Anti-TNF therapy is associated with an increased risk of serious infections in patients with rheumatoid arthritis especially in the first 6 months of treatment: updated results from the British Society for Rheumatology Biologics Register with special emphasis on risks in the elderly. Rheumatology 50:124–131PubMedCentralCrossRef
35.
Zurück zum Zitat Xie X, Li F, Chen JW, Wang J (2013) Risk of tuberculosis infection in atni-TNFα biological therapy: from bench to bedside. J Microbiol Immunol Infect 30:S1684–1182 Xie X, Li F, Chen JW, Wang J (2013) Risk of tuberculosis infection in atni-TNFα biological therapy: from bench to bedside. J Microbiol Immunol Infect 30:S1684–1182
36.
Zurück zum Zitat McCain GA, Harth M, Bell DA et al (1981) Septic Discitis. J Rheumatol 8:100–109PubMed McCain GA, Harth M, Bell DA et al (1981) Septic Discitis. J Rheumatol 8:100–109PubMed
37.
Zurück zum Zitat Fantoni M, Trecarichi EM, Rossi B et al (2012) Epidemiological and clinical features of pyogenic spondylodiscitis. Eur Rev Med Pharmacol Sci 2:2–7 Fantoni M, Trecarichi EM, Rossi B et al (2012) Epidemiological and clinical features of pyogenic spondylodiscitis. Eur Rev Med Pharmacol Sci 2:2–7
Metadaten
Titel
Spinal non-Hodgkin’s lymphoma mimicking a flare of disease in a patient with ankylosing spondylitis treated with anti-TNF agents: case report and review of the literature
verfasst von
Sara Monti
Nicola Boffini
Marco Lucioni
Marco Paulli
Carlomaurizio Montecucco
Roberto Caporali
Publikationsdatum
01.01.2016
Verlag
Springer London
Erschienen in
Clinical Rheumatology / Ausgabe 1/2016
Print ISSN: 0770-3198
Elektronische ISSN: 1434-9949
DOI
https://doi.org/10.1007/s10067-014-2594-2

Weitere Artikel der Ausgabe 1/2016

Clinical Rheumatology 1/2016 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

RAS-Blocker bei Hyperkaliämie möglichst nicht sofort absetzen

14.05.2024 Hyperkaliämie Nachrichten

Bei ausgeprägter Nierenfunktionsstörung steigen unter der Einnahme von Renin-Angiotensin-System(RAS)-Hemmstoffen nicht selten die Serumkaliumspiegel. Was in diesem Fall zu tun ist, erklärte Prof. Jürgen Floege beim diesjährigen Allgemeinmedizin-Update-Seminar.

Gestationsdiabetes: In der zweiten Schwangerschaft folgenreicher als in der ersten

13.05.2024 Gestationsdiabetes Nachrichten

Das Risiko, nach einem Gestationsdiabetes einen Typ-2-Diabetes zu entwickeln, hängt nicht nur von der Zahl, sondern auch von der Reihenfolge der betroffenen Schwangerschaften ab.

Labor, CT-Anthropometrie zeigen Risiko für Pankreaskrebs

13.05.2024 Pankreaskarzinom Nachrichten

Gerade bei aggressiven Malignomen wie dem duktalen Adenokarzinom des Pankreas könnte Früherkennung die Therapiechancen verbessern. Noch jedoch klafft hier eine Lücke. Ein Studienteam hat einen Weg gesucht, sie zu schließen.

Battle of Experts: Sport vs. Spritze bei Adipositas und Typ-2-Diabetes

11.05.2024 DDG-Jahrestagung 2024 Kongressbericht

Im Battle of Experts traten zwei Experten auf dem Diabeteskongress gegeneinander an: Die eine vertrat die Auffassung „Sport statt Spritze“ bei Adipositas und Typ-2-Diabetes, der andere forderte „Spritze statt Sport!“ Am Ende waren sie sich aber einig: Die Kombination aus beidem erzielt die besten Ergebnisse.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.